Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

In English

Författare

Summary, in English

Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family. This article reviews mechanisms of action and clinical data behind the use of these two commonly used oral hypoglycemic agents with documented efficacy and good safety profile of once-daily administration, alone or in combination with insulin or metformin, in the management of T2D in terms of glycemic and non-glycemic effects, tolerability and side effects, and impact on vascular health.

Publiceringsår

2007

Språk

Engelska

Sidor

721-731

Publikation/Tidskrift/Serie

Vascular Health and Risk Management

Volym

3

Issue

5

Dokumenttyp

Artikel i tidskrift

Förlag

Dove Medical Press Ltd.

Ämne

  • Cardiac and Cardiovascular Systems

Nyckelord

  • Sulfonylurea Compounds: therapeutic use
  • Thiazolidinediones: therapeutic use
  • Diabetes Mellitus
  • Sulfonylurea Compounds: adverse effects
  • Type 2: drug therapy
  • Type 2: blood
  • Blood Glucose: metabolism
  • Thiazolidinediones: adverse effects

Status

Published

Forskningsgrupp

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Övrigt

  • ISSN: 1178-2048